COVID-19: 3D Bioprinted Tissue Models for Respiratory Viruses
Document text
Principal Investigator: Marc Ferrer Organization: NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES Fiscal Year: 2022 Award: $90,219 Funding agency: National Center for Advancing Translational Sciences We have established protocols for culturing primary human small airway epithelial cells and alveolar cells in a transwell air-liquid-interface (ALI) model. Tissue biofabrication has been optimized in a 96-well plate format, including the formation of a microvessel network. We are positioning these lung tissue models platforms for testing infectivity of viral variants and anti-viral therapeutics for programs at NCATS, NIH and the broader research and drug development community. We have also developed a vascularized perfused lung epithelial tissue model in a high throughput microfluidics platform to assess of viral infection vasculature leakiness and permeability and thrombotic events seen in COVID-19 patients. We have characterized extensively the infectivity of the MatTek's tracheobronchial and alveolar cultures with SARS-CoV2 and IAV. We have also assessed the anti-viral effects of a focused number of compounds identified from HTS. In collaboration with Sara Cherry at the University of Pennsylvania, we have identified that Pharmacological activation of STING blocks SARS-CoV-2 infection. We continue to explore additional relevant therapeutic opportunities from drug screens at UPenn. We have worked with NICHD Sequencing Core lab and scientists at the Texas Biomedical Research Institute to implement scRNAseq studies on tracheobronchial and alveolar lung tissue models infected with IAV and SARS-CoV2. Some of the results have been published and some data analysis is currently on-going. We have assessed infectivity of intestine tissues (Mattek) and neural spheroids models with SARS-CoV2 Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><3-D><3-Dimensional><3D><Address><Air><Alveolar><Alveolar Cell><Antiviral Agents><Antiviral Drugs><Antivirals><Assay><Bioassay><Biologic Assays><Biological Assay><Biomedical Research><Blood Vessels><Body Tissues><Brain><Brain Nervous System><COVID associated pneumonia><COVID crisis><COVID epidemic><COVID induced pneumonia><COVID infected patient><COVID pandemic><COVID patient><COVID pneumonia><COVID positive patient><COVID related pneumonia><COVID-19><COVID-19 associated pneumonia><COVID-19 crisis><COVID-19 epidemic><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 induced pneumonia><COVID-19 infected patient><COVID-19 infection><COVID-19 pandemic><COVID-19 patient><COVID-19 pneumonia><COVID-19 positive patient><COVID-19 public health crisis><COVID-19 related pneumonia><COVID-19 therapy><COVID-19 treatment><COVID-19 virus><COVID19><COVID19 crisis><COVID19 epidemic><COVID19 global health crisis><COVID19 global pandemic><COVID19 health crisis><COVID19 infection><COVID19 pandemic><COVID19 patient><COVID19 positive patient><COVID19 public health crisis><COVID19 therapy><COVID19 treatment><COVID19 virus><CV-19><CV19><Cardiac><Cell Body><Cells><Clinical><CoV-2><CoV2><Collaborations><Communities><Community Developments><Coronaviridae><Coronavirus><DNA Sequencing Facility><Data Analyses><Data Analysis><Development and Research><Disease><Disorder><Drug Screening><Drugs><Encephalon><Epithelial><Epithelial Cells><Event><Funding><Human><Immune><Immunes><In Vitro><Infection><Influenza Virus><Intestinal><Intestines><Kidney><Kidney Urinary System><Laboratories><Liquid substance><Lung><Lung Parenchyma><Lung Respiratory System><Lung Tissue><Medication><Microfluidics><Modeling><Modern Man><NCATS><NIAID><NICHD><NIH><National Center for Advancing Translational Sciences><National Institute of Allergy and Infectious Disease><National Institute of Child Health and Human Development><National Institute of Children's Health and Human Development><National Institutes of Health><Pathology><Pennsylvania><Permeability><Pharmaceutic Preparations><Pharmaceutical Preparations><Pharmacology><Physiologic><Physiological><Position><Positioning Attribute><Protocol><Protocols documentation><Public Health><Publishing><R & D><R&D><Research Activity><Research Institute><Research Support><Respiratory Epithelium><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 associated pneumonia><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 induced pneumonia><SARS-CoV-2 infected patient><SARS-CoV-2 infection><SARS-CoV-2 inhibitor><SARS-CoV-2 pandemic><SARS-CoV-2 patient><SARS-CoV-2 pneumonia><SARS-CoV-2 positive patient><SARS-CoV-2 related pneumonia><SARS-CoV-2 therapy><SARS-CoV-2 treatment><SARS-CoV2><SARS-CoV2 epidemic><SARS-CoV2 infection><SARS-CoV2 pandemic><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Scientist><Sequencing Core><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 inhibitor><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome related corona virus 2><Societies><Structure of parenchyma of lung><Structure of respiratory epithelium><System><Testing><Texas><Therapeutic><Therapeutic Intervention><Tissue Model><Tissues><Tracheobronchial><Translational Research><Translational Science><United States National Institutes of Health><Universities><Vaccines><Variant><Variation><Viral><Viral Diseases><Viral Respiratory Tract Infection><Virus><Virus Diseases><Work><Wuhan coronavirus><airway epithelium><anti-viral agents><anti-viral compound><anti-viral drugs><anti-viral medication><anti-viral therapeutic><anti-virals><antiviral compound><antiviral medication><antiviral therapeutic><atypical pneumonia><beta CoV><beta coronavirus><betaCoV><betacoronavirus><bio-fabrication><bio-printing><biofabrication><bioprinting><block SARS-CoV-2><block severe acute respiratory syndrome coronavirus 2><bowel><clinical efficacy><corona virus><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><coronavirus disease 2019><coronavirus disease 2019 associated pneumonia><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 induced pneumonia><coronavirus disease 2019 infected patient><coronavirus disease 2019 infection><coronavirus disease 2019 pandemic><coronavirus disease 2019 patient><coronavirus disease 2019 pneumonia><coronavirus disease 2019 positive patient><coronavirus disease 2019 public health crisis><coronavirus disease 2019 related pneumonia><coronavirus disease 2019 therapy><coronavirus disease 2019 treatment><coronavirus disease 2019 virus><coronavirus disease associated pneumonia><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease induced pneumonia><coronavirus disease infected patient><coronavirus disease pandemic><coronavirus disease patient><coronavirus disease pneumonia><coronavirus disease positive patient><coronavirus disease related pneumonia><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 pandemic><coronavirus disease-19 patient><coronavirus disease-19 pneumonia><coronavirus disease-19 virus><coronavirus infectious disease-19><coronavirus patient><data interpretation><drug development><drug repurposing><drug/agent><fluid><hCoV19><in vitro Assay><in vivo><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><influenzavirus><inhibit SARS-CoV-2><inhibit severe acute respiratory syndrome coronavirus 2><intervention therapy><liquid><nCoV2><neural><novel><pandemic><pandemic disease><parainfluenza virus><patient infected with COVID><patient infected with COVID-19><patient infected with SARS-CoV-2><patient infected with coronavirus disease><patient infected with coronavirus disease 2019><patient infected with severe acute respiratory syndrome coronavirus 2><patient with COVID><patient with COVID-19><patient with COVID19><patient with SARS-CoV-2><patient with coronavirus disease><patient with coronavirus disease 2019><patient with severe acute respiratory distress syndrome coronavirus 2><pneumonia due to COVID><pneumonia due to COVID-19><pneumonia due to SARS-CoV-2><pneumonia due to coronavirus disease><pneumonia due to coronavirus disease 2019><pneumonia due to severe acute respiratory syndrome coronavirus 2><pneumonia in COVID><pneumonia in COVID-19><pneumonia in SARS-CoV-2><pneumonia in coronavirus disease><pneumonia in coronavirus disease 2019><pneumonia in severe acute respiratory syndrome coronavirus 2><programs><pulmonary><relating to nervous system><renal><repurposing agent><repurposing medication><research and development><respiratory><respiratory pathogen><respiratory virus><response><screening><severe acute respiratory syndrome coronavirus 2 associated pneumonia><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 induced pneumonia><severe acute respiratory syndrome coronavirus 2 infected patient><severe acute respiratory syndrome coronavirus 2 patient><severe acute respiratory syndrome coronavirus 2 pneumonia><severe acute respiratory syndrome coronavirus 2 positive patient><severe acute respiratory syndrome coronavirus 2 related pneumonia><severe acute respiratory syndrome coronavirus 2 therapy><severe acute respiratory syndrome coronavirus 2 treatment><therapeutic agent development><therapeutic development><three dimensional><thrombotic><translation research><treat COVID-19><treat COVID19><treat SARS-CoV-2><treat coronavirus disease 2019><treat severe acute respiratory syndrome coronavirus 2><vascular><viral infection><viral respiratory infection><virus infection><virus-induced disease><µfluidic><β CoV><β coronavirus><βCoV>